Research ExplorerPublicationsAutoimmune diabetic patients undergoing allogeneic islet tra...

Autoimmune diabetic patients undergoing allogeneic islet transplantation

Standard

Autoimmune diabetic patients undergoing allogeneic islet transplantation : are we ready for a regulatory T-cell therapy? / Gagliani, Nicola; Ferraro, Alessandra; Roncarolo, Maria Grazia; Battaglia, Manuela.

In: IMMUNOL LETT, Vol. 127, No. 1, 02.12.2009, p. 1-7.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Gagliani, N, Ferraro, A, Roncarolo, MG & Battaglia, M 2009, 'Autoimmune diabetic patients undergoing allogeneic islet transplantation: are we ready for a regulatory T-cell therapy?', IMMUNOL LETT, vol. 127, no. 1, pp. 1-7. https://doi.org/10.1016/j.imlet.2009.07.007

APA

Gagliani, N., Ferraro, A., Roncarolo, M. G., & Battaglia, M. (2009). Autoimmune diabetic patients undergoing allogeneic islet transplantation: are we ready for a regulatory T-cell therapy? IMMUNOL LETT, 127(1), 1-7. https://doi.org/10.1016/j.imlet.2009.07.007

Vancouver

Gagliani N, Ferraro A, Roncarolo MG, Battaglia M. Autoimmune diabetic patients undergoing allogeneic islet transplantation: are we ready for a regulatory T-cell therapy? IMMUNOL LETT. 2009 Dec 2;127(1):1-7. https://doi.org/10.1016/j.imlet.2009.07.007

Bibtex

@article{8414a084c3904071b090b2547aeddbc0,
title = "Autoimmune diabetic patients undergoing allogeneic islet transplantation: are we ready for a regulatory T-cell therapy?",
abstract = "Regulatory T cells (Tregs) are thought to be pivotal in controlling both autoimmune and allogeneic undesired immune responses. Recently, an extensive effort has been devoted to design clinical trials with Tregs in T cell-mediated diseases (such as autoimmune diseases or transplantation). Theoretically, this approach can be used also in patients with autoimmunity (e.g., type 1 diabetes) undergoing allogeneic transplantation (e.g., pancreatic islet transplant). However, in this latter case Tregs must control two distinct effector immune responses: a pre-existing response towards self-antigens and a de novo response induced by the newly transplanted allogeneic cells. In this review we summarize results supporting the use of Tregs in controlling either autoimmunity or allo-transplantation. We also provide our view on how Treg therapy can achieve the final goal of immunological tolerance in the extremely challenging clinical setting of type 1 diabetic subjects transplanted with allogeneic islets.",
keywords = "Animals, Autoimmunity, Diabetes Mellitus, Type 1, Graft Rejection, Humans, Immune Tolerance, Immunotherapy, Adoptive, Islets of Langerhans Transplantation, T-Lymphocytes, Regulatory, Transplantation, Homologous, Journal Article, Research Support, Non-U.S. Gov't, Review",
author = "Nicola Gagliani and Alessandra Ferraro and Roncarolo, {Maria Grazia} and Manuela Battaglia",
year = "2009",
month = dec,
day = "2",
doi = "10.1016/j.imlet.2009.07.007",
language = "English",
volume = "127",
pages = "1--7",
journal = "IMMUNOL LETT",
issn = "0165-2478",
publisher = "Elsevier",
number = "1",

}

RIS

TY - JOUR

T1 - Autoimmune diabetic patients undergoing allogeneic islet transplantation

T2 - are we ready for a regulatory T-cell therapy?

AU - Gagliani, Nicola

AU - Ferraro, Alessandra

AU - Roncarolo, Maria Grazia

AU - Battaglia, Manuela

PY - 2009/12/2

Y1 - 2009/12/2

N2 - Regulatory T cells (Tregs) are thought to be pivotal in controlling both autoimmune and allogeneic undesired immune responses. Recently, an extensive effort has been devoted to design clinical trials with Tregs in T cell-mediated diseases (such as autoimmune diseases or transplantation). Theoretically, this approach can be used also in patients with autoimmunity (e.g., type 1 diabetes) undergoing allogeneic transplantation (e.g., pancreatic islet transplant). However, in this latter case Tregs must control two distinct effector immune responses: a pre-existing response towards self-antigens and a de novo response induced by the newly transplanted allogeneic cells. In this review we summarize results supporting the use of Tregs in controlling either autoimmunity or allo-transplantation. We also provide our view on how Treg therapy can achieve the final goal of immunological tolerance in the extremely challenging clinical setting of type 1 diabetic subjects transplanted with allogeneic islets.

AB - Regulatory T cells (Tregs) are thought to be pivotal in controlling both autoimmune and allogeneic undesired immune responses. Recently, an extensive effort has been devoted to design clinical trials with Tregs in T cell-mediated diseases (such as autoimmune diseases or transplantation). Theoretically, this approach can be used also in patients with autoimmunity (e.g., type 1 diabetes) undergoing allogeneic transplantation (e.g., pancreatic islet transplant). However, in this latter case Tregs must control two distinct effector immune responses: a pre-existing response towards self-antigens and a de novo response induced by the newly transplanted allogeneic cells. In this review we summarize results supporting the use of Tregs in controlling either autoimmunity or allo-transplantation. We also provide our view on how Treg therapy can achieve the final goal of immunological tolerance in the extremely challenging clinical setting of type 1 diabetic subjects transplanted with allogeneic islets.

KW - Animals

KW - Autoimmunity

KW - Diabetes Mellitus, Type 1

KW - Graft Rejection

KW - Humans

KW - Immune Tolerance

KW - Immunotherapy, Adoptive

KW - Islets of Langerhans Transplantation

KW - T-Lymphocytes, Regulatory

KW - Transplantation, Homologous

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

KW - Review

U2 - 10.1016/j.imlet.2009.07.007

DO - 10.1016/j.imlet.2009.07.007

M3 - SCORING: Review article

C2 - 19643137

VL - 127

SP - 1

EP - 7

JO - IMMUNOL LETT

JF - IMMUNOL LETT

SN - 0165-2478

IS - 1

ER -